Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Status:
Completed
Trial end date:
2021-10-14
Target enrollment:
Participant gender:
Summary
Coagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is
associated with need for critical care and death. COVID-19 coagulopathy is characterized by
elevated D-dimer, an indicator of fibrin formation and clot lysis, and a mildly prolonged
prothrombin time, suggestive of coagulation consumption. To date, it seems that COVID-19
coagulopathy manifests with thromboembolism, thus anticoagulation may be of benefit. We
propose to conduct a parallel pragmatic multi-centre open-label randomized controlled trial
to determine the effect of therapeutic anticoagulation compared to standard care in
hospitalized patients admitted for COVID-19 with an elevated D-dimer.
Phase:
Phase 3
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
Al Ain Hospital Barnes-Jewish Hospital Foothills Medical Centre Hôpital Charles Lemoyne Hopital du Sacre-Coeur de Montreal Hospital Maisonneuve-Rosemont King Fahad Medical City King Faisal Specialist Hospital King Saud University Medical City Mater Misericordiae University Hospital Michael Garron Hospital MOUNT SINAI HOSPITAL Peter Lougheed Centre Queen Elizabeth II Health Sciences Centre Rockyview General Hospital Southlake Regional Health Centre St. Joseph's Health Centre The Ottawa Hospital Trillium Health Partners University of Alberta University of Sao Paulo University of Vermont Medical Center Versiti William Osler Health System